Since its inception in early 1999, BD Ventures has invested in a number of startup companies. A representative list of BD Ventures' active investments are described below; each is a venture capital-backed company developing proprietary products and technologies for medical markets.

Aureon Laboratories, Inc. (Yonkers, NY) is developing and marketing predictive clinical tests for cancer care.  Aureon's personalized predictive pathology technology has the potential to significantly advance the state of clinical medicine.

Cellerant Therapeutics, Inc. (San Carlos, CA) is a clinical-stage biotechnology company with a portfolio of products based on the regulation of the hematopoietic (blood-forming) system. The company focuses on curative therapies for application in cancer, genetic blood disorders and autoimmune diseases.

Novocell, Inc. (Irvine, CA) is a stem cell engineering company creating, delivering, and commercializing cell and drug therapies for diabetes and other chronic diseases.  Novocell is focused on three platform technologies that will address the need for an unlimited supply of specialized human cells for the treatment and cure of a wide range of chronic cellular diseases: human embryonic stem cell engineering, cellular delivery, and drug discovery.

Progenitor Cell Therapy, LLC (Hackensack, NJ) is a client-based cell therapy services company that supports the development of cellular therapies by providing cGMP-compliant cell manufacturing and consulting services that address regulatory, financial, technical, process, and quality systems needs.

RenaMed Biologics, Inc. (Lincoln, RI, formerly Nephros Therapeutics, Inc.) is a biotechnology company focused on the development and commercialization of therapies for the treatment of diseases associated with compromised kidney function. RenaMed’s products are designed to dramatically improve the clinical outcome and cost of care for patients suffering from Acute Renal Failure and additional indications where kidney function is compromised.